Skip to main content

Table 1 Mean values, Intra-individual (CVI) and Inter-individuals (CVG) coefficient of variation, and index of individuality (II) of blood level of basic Lipid panel of HIV-1 infected and uninfected men

From: Long-term intra- and inter-individual biological variation of serum lipid of HIV-infected and uninfected men participating in the Los Angeles Multi-Center AIDS Cohort Study (MACS)

Participants HIV-1 uninfected Men HIV-1 infected Men
Subject number 77 men on CLDs* ^63 men not on CLDs 62 men on CLDs ^28 men not on CLDs
Visit number 3 34 3 34 3 34 3 34
Follow up year 1 17 1 17 1 17 1 17
Assay Blood level of total cholesterol Blood level total cholesterol
Obs # 215 2255 148 1714 162 1743 66 736
Mean (mg/dL) 196.1 189.9 181.9 193.4 189.4 184.2 165.2 175.1
Standard Error 3.44 3.24 3.91 3.37 5.03 3.63 7.82 6.38
CVI (%) 10.6 16.1 10.2 11.0 13.6 18.6 10.0 13.4
CVG (%) 13.8 14.3 14.7 13.3 18.5 14.9 22.6 18.6
II 0.77 1.12 0.69 0.83 0.74 1.25 0.44 0.72
Assay Blood level of Triglycerides Blood level of Triglycerides
Obs # 201 2147 132 1577 155 1641 64 638
Mean (mg/dL) 126.8 120.6 91.3 93.1 239.6 188.1 130.2 129.3
Standard Error 8.43 5.32 5.97 4.39 22.25 12.7 19.50 11.54
CVI (%) 40.7 43.8 33.6 36.6 60.4 69.0 40.0 47.0
CVG (%) 50.8 36.6 41.7 34.9 59.3 50.4 90.0 43.7
II 0.80 1.20 0.81 1.05 1.02 1.37 0.44 1.08
Assay Blood level of HDL-C Blood level of HDL-C
Obs # 215 2252 148 1713 161 1736 67 730
Mean (mg/dL) 47.4 50.8 49.4 55.2 39.6 45.1 45.1 47.2
Standard Error 1.15 1.15 1.11 1.25 1.27 1.41 4.19 3.17
CVI (%) 13.4 15.9 14.1 13.8 16.0 19.5 16.7 19.6
CVG (%) 19.3 19.3 14.2 17.6 22.4 23.9 44.9 34.3
II 0.69 0.82 0.99 0.79 0.71 0.82 0.37 0.57
Assay Blood level of LDL-C Blood level of LDL-C
Obs # 209 2205 147 1696 132 1512 60 654
Mean (mg/dL) 124.1 114.3 113.8 118.6 114.5 105.8 97.8 102.3
Standard Error 3.01 2.91 3.45 3.17 5.40 3.31 5.61 4.28
CVI (%) 15.8 24.9 15.8 15.8 21.4 27.3 16.2 20.8
CVG (%) 18.6 21.4 20.3 20.3 30.9 23.1 25.2 20.6
II 0.85 1.16 0.78 0.78 0.69 1.18 0.64 1.01
  1. * CLDs Cholesterol lowering drugs (statins or other), data of ^63 out of 140 HIV-1 uninfected men and ^28 out 90 HIV-1 infected men not on CLDs, Obs#; number of available observation data used for the analysis of one and seventeen years follow up